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G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-
induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains
unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER−/PR+
breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity
in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-
mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of
PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to
reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs,
suggesting that GPER is a potential therapeutic target for eradicating BCSCs.
*Y.-T.C. and A.C.-Y.L. contributed equally to this work
Author contributions: Conception and design: Chen Y-J, Yu AL, Lai AC-Y, Chan Y-T, Chang W-W. Performed research: Lai AC-Y, Chan
Y-T, Wang Y-T, Wu H-Y, Lin R-J, Lin Y-J, Wang Y-H, Chang W-Y, Wu J-C. Provision of clinical specimens: Yu J-C. Manuscript writing: Lai
AC-Y, Chan Y-T, Yu AL. Final approval of manuscript: Chen Y-J, Yu AL. Review of the manuscript: all authors.
Additional Supporting Information may be found in the online version of this article.
Key words: GPER, breast cancer stem cell, phosphoproteomics, BAD, tamoxifen
Abbreviations: 4-OHT: 4-hydroxytamoxifen; ALDH: aldehyde dehydrogenases; BCSC: breast cancer stem cell; CTTN: cortactin; DEAB:
diethylaminobenzaldehyde; E2: 17β-estradiol; E3: estriol; EGFR: epidermal growth factor receptor; ER: estrogen receptor; GPCR: G protein-
coupled receptor; GPER: G protein-coupled estrogen receptor-1; HER2: human epidermal growth factor receptor 2; IMAC: immobilized metal
affinity chromatography; LC–MS/MS: liquid chromatography-tandem mass spectrometry; MAPK: mitogen-activated protein kinase; PDX:
patient-derived xenograft; PR: progesterone receptor; RFS: relapse-free survival; SERM: selective estrogen receptor modulator; shRNA: short
hairpin RNA; TMX: tamoxifen; WT: wild-type
Conflict of interest: Authors declare no conflict of interests.
Grant sponsor: Academia Sinica; Grant number: 97-2628-M-001-020-MY3; Grant sponsor: Chang Gung Medical Foundation;
Grant numbers: OMRPG3C0012, OMRPG3C0013; Grant sponsor: Ministry of Science and Technology in Taiwan; Grant numbers: MOST
103-2321-B-182A-002, MOST 104-2321-B-182A-004, NSC102-2321-B-182A-005
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations
are made.
DOI: 10.1002/ijc.32588
History: Received 24 Oct 2018; Accepted 25 Jun 2019; Online 24 Jul 2019
Correspondence to: Yu-Ju Chen, Institute of Chemistry, Academia Sinica, Taipei, Taiwan, Tel.: +886-2-27898660, Fax: +886-2-27831237,
E-mail: yujuchen@gate.sinica.edu.tw; or Alice L. Yu, Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital
at Linkou and Chang Gung University, Taoyuan, Taiwan, Tel.: +886-3-3281200, Fax: +886-3-3285060, E-mail: a1yu@ucsd.edu
International Journal of Cancer
IJC
Int. J. Cancer: 146, 1674–1685 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
Introduction
The biological characteristics and clinical behavior of breast
cancer are heterogeneous; breast cancer subtypes are assigned
according to the presence of three receptors: the estrogen
receptor (ER), the progesterone receptor (PR) and human epi-
dermal growth factor receptor 2 (HER2). Estrogens, as ligands
of the ER, control the normal growth and differentiation of
human breast epithelial cells, and long term exposure to an
excess amount of estrogen may promote the development of
breast cancer.1 Approximately 70% of breast cancers express
hormone receptors and are amenable to endocrine therapy.
Tamoxifen (TMX), the most commonly used antiestrogen
drug, is a selective ER modulator (SERM) that activates/
inhibits ER in cell type- and context-dependent manner.2
Another antiestrogen drug, fulvestrant, destabilizes ER upon
binding and promotes ER degradation.3 Besides these SERMs,
aromatase inhibitors are effective as therapeutic agents by
blocking estrogen production.4 However, about one-third of
patients treated with adjuvant TMX develop aggressive recur-
rent disease, which is attributed to the activation of escape
pathways, providing tumors with alternative proliferative and
survival stimuli.5 Emerging evidence has implicated G
protein-coupled estrogen receptor-1 (GPER, formerly known
as GPR30) in TMX resistance. Binding of estrogen to GPER, a
member of the G protein-coupled receptor (GPCR) superfam-
ily, activates adenylyl cyclase, causing the release of cAMP.6 In
addition, estrogen activates GPER to promote epidermal
growth factor receptor (EGFR) dimerization and downstream
activation of the mitogen-activated protein kinase (MAPK)
signaling axis.7 It has been reported that GPER activation
stimulates the migration of breast cancer cells in vitro, and
promotes metastasis in vivo.8,9 Of note, ER antagonists such
as TMX and fulvestrant act as agonists for GPER and stimu-
late cell proliferation.10,11 Moreover, binding of TMX to GPER
induced aromatase expression to sustain TMX-resistant breast
cancer cell growth.12 These findings are in line with the clini-
cal observation that TMX treatment resulted in poorer
relapse-free survival (RFS) in patients with GPER-positive
tumors than those with GPER-negative tumors.13 In contrast
to the above-mentioned tumorigenic role of GPER, a few
studies have shown that GPER can act as an inhibitor on the
proliferation of breast cancer cells.14 Besides, the role of GPER
in breast cancer stem cells (BCSCs) has yet to be addressed.
The existence of cancer stem cells, which exhibit the stem cell-
like properties of self-renewal and differentiation, has been well-
documented.15 In breast cancer, cells with a CD44+CD24−/low sur-
face antigen profile or those with high activities of aldehyde dehy-
drogenases (ALDH) are considered to be enriched BCSCs, based
on their capacity for mammosphere formation in vitro and tumor-
igenesis in vivo and their ability for yielding heterogeneous pheno-
types including non-CD44+CD24−/low or ALDHlow population.16
Approximately 74% of recurrent tumors contain a subpopulation
of CD44+CD24−/low cells as compared to 9% of tumors in
untreated patients, implying that BCSCs may be more resistant to
therapy and, therefore, an important target for treating breast can-
cer.15 Indeed, BCSCs are relatively resistant to radiation and che-
motherapy, accounting for their increased frequency in residual
tumor after fractionated irradiation17 or chemotherapy.18 Finally,
an increased percentage of CD44+CD24−/low or ALDHhigh cells
has also been observed in tumors that remain after neoadjuvant
endocrine therapy, suggesting a subpopulation of hormone-
resistant BCSCs.18,19 Consistent with the unique properties that
confer BCSC resistance to therapy, BCSCs have been reported to
undergo constitutive activation of signal transduction pathways
related to stem-cell functions. It has been shown that the
PTEN/mTOR/STAT3 pathway is essential in maintaining the sur-
vival and proliferation of the cancer stem cell-like subpopulation
of the MCF-7 breast cancer cell line.20 Likewise, the IGF-
1R/PI3K/AKT/mTOR pathway has been reported to regulate
BCSC proliferation.21 Although the aforementioned signal trans-
duction pathways appear to affect BCSC biology, most of these
studies used cancer cell lines that have been passaged in vitro for
years and may not reflect the true biology of BCSCs in vivo. A
thorough understanding of the nature of BCSCs requires a sys-
tematic and in-depth analysis of the signal transduction abnor-
malities within BCSCs harvested from patient-derived xenografts
(PDXs), which may enhance the knowledge on cancer pathogene-
sis and unveil novel therapeutic targets.
To elucidate the roles of GPER in BCSCs, we applied a
quantitative phosphoproteomics analysis to systematically
compare the BCSCs and non-BCSCs isolated from a PDX of
ER− breast cancer to better understand the roles of GPER in
BCSCs and to elucidate GPER-mediated signaling contribut-
ing to BCSC biological features. We uncovered a complex
interplay of upregulated signaling pathways associated with
the stemness and survival of BCSCs. Among the differentially
regulated pathways, we showed that PKA/BAD is one of sig-
naling cascades regulated by GPER in BCSCs, which offers an
alternative mechanism of estrogen-mediated BCSC survival, in
addition to the well-known ER pathway.
What’s new?
G protein-coupled estrogen receptor-1 (GPER) mediates estrogen-induced proliferation of normal and malignant breast epithelial
cells. However, the role of GPER in breast cancer stem cells (BCSC) biology remains unclear. Here, using patient-derived xenografts
of ER–/PR+ breast cancer, the authors found higher expression of GPER in BCSCs than non-BCSCs. Moreover, the results indicated
that stemness features were sustained via GPER-mediated PKA/BAD phosphorylation. Stimulation by the GPER ligand tamoxifen
enhanced BCSC cell viability and population and BAD phosphorylation. The findings revealed a vital role of GPER-mediated
signaling pathways in BCSC survival, suggesting GPER as a potential therapeutic target for eradicating BCSCs.
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Materials and Methods
Isolation and maintenance of primary human breast cancer
xenografts
Isolation of primary tumor cells and maintenance of xenografts
were performed as previously described.22 Briefly, the tumor spec-
imens were enzymatically digested by collagenase (1,000 U/ml),
hyaluronidase (300 U/ml), and DNase I (100 μg/ml) at 37C for
1 hr. Then, tumor cells were filtrated through a 100 μM cell
strainer and removed from red blood cells and dead cells by
Percoll density gradient centrifugation. Cells resided in buffy coat
were washed and resuspended by RPMI1640 medium sup-
plemented with 5% FBS for flow cytometric analysis.
Cell culture and reagents
AS-B145 andAS-B634 cells were derived fromH2Kd–CD24−CD44+
BCSCs of the BC0145 and H2Kd–ALDH+ BCSCs of the BC0634
xenograft, respectively, and cultured in modified Eagle’s medium,
10% (v/v) fetal bovine serum, 10 μg/ml insulin at 37C with 5%
CO2.
22,23 E2 (Cat. #10006315), E3 (Cat. #10006484) and G1 (Cat.
#100088933) were purchased from Cayman Chemical (Ann Arbor,
MI). 4-Hydroxytamoxifen (4-OHT; Cat. #H7904) was purchased
from Sigma (St. Louis,MO).
RT-qPCR of GPER mRNA
Total RNA from AS-B145 cells was isolated using TRIzol
reagent (Cat. #15596–026, Invitrogen, Carlsbad, CA). Total
RNA (1 μg) was reverse transcribed into cDNA using TaqMan
Reverse Transcription Reagents (Cat. #N8080234, Applied Bio-
systems, Foster City, CA). FastStart SYBR Green Master (Cat.
#04673484001, Roche Applied Science, Indianapolis, IN) was
used for RT-qPCR and analyzed using a 7300 Sequence Detec-
tion System (Applied Biosystems). Briefly, 10 ng of cDNA and
GPER-specific primers were used for qPCR amplification. The
threshold cycle (Ct) values were determined using the default
threshold settings. Total initial RNA was normalized to the Ct
values of the internal control, GAPDH. The primer sequences
for GPER, GPERF01 and GPERR01, are shown in Supporting
Information Table S2.
Knockdown of GPER expression by lentiviral short
hairpin RNA
All lentiviral short hairpin RNA (shRNA) plasmids are
listed in Supporting Information Table S3. These shRNAs
were purchased from the National RNAi Core Facility of
the Institute of Molecular Biology/Genomics Research Cen-
ter, Academia Sinica, Taiwan. The shRNA plasmid against
luciferase served as a negative control (shLuc). The proce-
dure for lentiviruses production was described previously.22
At 24 hr after seeding, cells were infected by viruses at a
multiplicity of infection (MOI) of 2 with the addition of
8 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO). Puromy-
cin (Sigma-Aldrich) selection (2 μg/ml) was administered
24 hr after infection.
Gel-assisted digestion and IMAC-facilitated phosphopeptide
purification
Cells were lysed in 0.25 M Tris–HCl (pH 6.8) and 1% (w/v)
SDS. Cell lysate protein samples (800 μg) spiked with 0.1 μg
of β-casein (internal standard) were each incorporated directly
into an acrylamide gel (acrylamide/bisacrylamide solution
(40%, (v/v), 29:1), 10% (w/v) ammonium persulfate, 100%
N,N,N0,N0-tetramethylenediamine at a 14.5:0.7:0.3 ratio) in an
Eppendorf tube. Each gel was chopped into pieces and washed
three times with 50% (v/v) acetonitrile (ACN) in 25 mM
triethylammonium bicarbonate (TEABC) to remove detergent.
The gels were then dehydrated by soaking in 100% ACN and
were completely dried by vacuum centrifugation in a Savant
SpeedVac® concentrator (Thermo Fisher Scientific, Waltham,
MA). For proteolysis, each dried gel sample was immersed in
25 mM TEABC that contained trypsin (protein/trypsin = 40:1,
w/w) and was incubated overnight at 37C. Tryptic peptides were
extracted three times in 5% (v/v) formic acid (FA)/50% (v/v) ace-
tonitrile (ACN) for 30 min and completely dried by vacuum cen-
trifugation at room temperature. IMAC was performed as
previously described with minor modifications.24,25 The IMAC
column was enclosed in a stainless steel column that was fitted
with a 0.5-μm frit disk at one end. Ni-NTA resin (Qiagen, Ger-
mantown, MD) was packed in a 10-cm microcolumn (500-μm
i.d. PEEK column, Upchurch Scientific/Rheodyne, Oak Harbor,
WA) for phosphopeptide purification, which was performed
using an autosampler, an HP1100 solvent delivery system
(Hewlett-Packard, San Jose, CA) with a flow rate of 13 μl/min,
and a loading/conditioning buffer of 6% (v/v) acetic acid
(pH 3.0). The enrichment protocol consisted of the following
steps: (i) removal of Ni2+ with the addition of 100 μl of 50 mM
EDTA in 1 M NaCl; (ii) activation of the IMAC column with
100 μl of 0.2 M FeCl3 and equilibration with loading buffer for
30 min; (iii) loading of peptide samples in loading buffer onto the
IMAC column; (iv) removal of unbound peptides with 100 μl of
25% (v/v) ACN, followed by equilibration with loading buffer for
15 min; (v) elution of bound peptides in 100 μl of 200 mM
NH4H2PO4 and drying by vacuum centrifugation prior to desa-
lting and concentration using ZipTips (Millipore, Burling-
ton, MA).
Liquid chromatography-tandem mass spectrometry
Purified phosphopeptides were dissolved in aqueous 0.1%
(v/v) TFA. For LC–MS/MS (Q-TOF Premier mass spectrome-
ter, Waters Corp., Milford, MA), samples were individually
injected into a 2-cm × 180-μm capillary-trap column and sep-
arated through a 75-μm × 25-cm nanoACQUITY 1.7-μm
BEH C18 column controlled by a nanoACQUITY Ultra-
Performance LC system (Waters Corp). Peptides were eluted
in aqueous 0.1% FA that contained a gradient of 0–80% ACN
over 120 min. The mass spectrophotometer was operated in
the ESI-positive V mode with a resolving power of 10,000. A
NanoLockSpray source was used for accurate mass measure-
ment, and the lock mass channel was sampled every 30 s. The
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spectrometer was calibrated with a synthetic human [Glu1]-
fibrinopeptide B (1 pmol/μl, Sigma Aldrich) delivered through
the NanoLockSpray source. Data acquisition was operated in
the data-directed mode and included a full MS scan
(400–1,600 m/z, 0.6 s) and three MS/MS scans (100–1,990 m/z,
1.2 s per scan) of the three most intense ions in the full scan
mass spectrum.
Database searching and quantification by IDEAL-Q
Quantification of proteins in the phosphoproteome was per-
formed as previously described with minor modifications.25,26
Raw MS/MS data were converted into peak lists using Distiller
(Matrix Science, Boston, MA; version 2.0) and default param-
eters. All MS/MS samples were subjected to a Mascot (Matrix
Science; version 2.2.1) search of the IPI_HUMAN_3.29 (ver-
sion 3.29, 68,161 entries) and Swiss-Prot_Metazoa_Animals
(version 54.2, 17,170 entries) databases with the following
parameters. The parent- and fragment-ion mass tolerances
were each 0.1 Da. Two missing tryptic cleavages were allowed.
Ser/Thr/Tyr phosphorylation and Met oxidation were allowed
but not required. The protein identification was based on the
significant Mascot score (p < 0.05). The raw data were
converted into mzXML-formatted files, and the MASCOT
search results were exported into eXtensive Markup Language
data (.XML)-formatted files. Quantification of the extracted
ion chromatogram (XIC) of each phosphopeptides and the
fold-change were performed using IDEAL-Q.26
Bioinformatics
For the annotation of subcellular localization, molecular func-
tion and biological process, the proteins were characterized by
GoMiner.27 To identify signaling pathways that contained the
differentially regulated phosphoproteins, the pathway analysis
tool MetaCore was used and augmented by literature min-
ing.28 The resulting annotation was organized using Excel and
presented in graphical formats.
Tumorigenicity in vivo
AS-B145 and AS-B634 cells were infected with lentiviral
shRNAs for 6 days. shGPER clone #B was used for GPER
knockdown. A total of 1 × 105 or 5 × 104 of the viable
puromycin-resistant AS-B145 or AS-B634 cells were mixed
with matrigel for subcutaneous injection into the mammary
fat pads of 6 or 5 NSG mice, respectively. Tumor formation
was monitored weekly after inoculation.
Statistical analysis
The significance of the cell proliferation experiments was
determined by one-way ANOVA with Holm-Sidak’s multiple
comparisons. To compare the growth of AS-B145 cells
expressing the mutant BAD (Ser118Ala), wild-type BAD and
vector, cell index at 96 hr was analyzed. The effects of
chemicals treatment on GPER+ population and ALDH+ popu-
lation were analyzed by one-way ANOVA with Holm–Sidak’s
multiple comparisons. For mammosphere formation and
mean percentages of ALDH+ cells in the total tumor cell pop-
ulation experiments, data were presented as mean  SD and
analyzed by Student’s t-test. A value of p < 0.05 was consid-
ered as significant.
Data availability
Data available on request from the authors.
Results
Greater expression of GPER in BCSCs than in non-BCSCs
To examine the role of GPER in BCSCs, we exploited our previ-
ously established PDXs of breast cancer, including BC0145,
BC0244 and BC0634, in which their BCSCs were identified as
H2Kd−CD24−CD44+ subpopulation for BC0145 and BC0244
and H2Kd−ALDH+ for BC0634, based on their higher tumorige-
nicity and re-emergence of tumor heterogeneity as the parental
tumors.21,23 The clinical–pathological features of these three
tumors are shown in Figure 1a. Both BC0145 and BC0634
tumor were ER-negative, PR-positive and HER2-positive.
BC0244 was ER-negative, PR-positive and HER2-negative. The
expression of GPER in the BCSCs and non-BCSCs of the three
PDXs was examined by western blotting. As shown in
Figure 1b, multiple bands of GPER were detected in the BCSCs
of each of the three tumors, which might reflect posttransla-
tional modifications in the form of N-linked glycosylation or
ubiquitination.29,30 GPER silencing by shRNA revealed that
multiple bands with a molecular mass of 50–55 kDa were GPER
(Fig. 2a). When normalized to the GAPDH band of the
corresponding samples, the amounts of GPER in BCSCs from
all three PDXs were higher than their non-BCSC counterparts
(Fig. 1b). To further validate the greater abundance of GPER-
positive cells in the BCSC population, we first identified CSC-
enriched and non-CSC populations of cancer cells derived from
PDXs BC0145 and BC0244, based on their CD44/CD24 pheno-
types (Fig. 1c), and determined their expression of GPER by
FACS analyses. For BC0145, 29.7% of the cells were GPER+/
CD44+ and 10.2% were GPER+/CD44−. For BC0244, 44.8% of
the cells were GPER+/CD44+ and only 4.7% were GPER+/
CD44−. The results showed that GPER+ cells were enriched in
the CSC population, suggesting that GPER may play a role in
the maintenance of BCSC properties.
Knockdown of GPER reduced the viability and stemness of
BCSCs
To decipher the importance of GPER in maintaining BCSC
characteristics, we knocked down GPER expression with spe-
cific shRNAs (shGPERs) in AS-B145, a cell line derived from
BCSCs of BC0145.21 After infection of AS-B145 cells with
three shGPER clones, GPER expression was decreased to
43 and 56% of control by clone B and C, respectively (Fig. 2a,
left panel). The proliferation of shRNAs infected AS-B145
cells was monitored using the xCELLigence system. As shown
in Figure 2a (center panel), shGPER infected cells had a lower
Chan et al. 1677
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cell index than controls, indicating that GPER depletion
impeded cell growth. To further confirm this, we also silenced
GPER expression in another ER-negative BCSC cell line, AS-
B634, which was derived from BCSCs of the BC0634 PDX.
Effective silencing of GPER expression to 9, 5 and 20% of
control by shRNA clones A, B and C, respectively, was
observed in AS-B634 cells (Fig. 2a, left panel) along with sig-
nificant suppression of the proliferation of shGPER infected
cells (Fig. 2a, right panel). We also verified the role of GPER
in BCSC (H2Kd−/CD24−/CD44+ cells) freshly isolated from
the BC0145 xenograft. As shown in Figure 2b, mRNA and
protein level of GPER declined to 50 and 62% of control by
shGPER clone B (sh-B), respectively. Similar results were
observed in H2kd− BC0634 cells, which were freshly isolated
from BC0634 xenograft. The GPER expression of mRNA and
protein were silenced to 24 and 45% of control by clone B in
BC0634. Furthermore, the proliferation of shRNAs infected
BC0145 and BC0634 cells was significantly stunted in shGPER
infected cells as shown in Figure 2c. Next, we examined the
effect of GPER silencing on their mammosphere-forming
capacity. As shown in Figure 2d, the average numbers of
mammospheres formed diminished from 18.2  1.3 to
7.5  1.4 for BC0145 cells infected with control shRNA
(shLuc) and shGPER, respectively (p < 0.001). Similar results
were observed in BC0634, with the reduction in the number
of mammospheres from 8.2  2.1 to 1.7  1.3 (p < 0.001) for
cells infected with shLuc and shGPER, respectively.
Identification of the key cellular machinery in BCSCs
revealed by phosphoproteomics
To decipher the GPER-related signaling pathway contributing to
BCSC properties, we applied quantitative phosphoproteomic
analysis to systematically compare the CSCs and non-CSCs of
BC0145 using our previously reported informatics-assisted label-
free mass spectrometry approach.25,26 After the internal standard
β-casein was added to the cell lysate of isolated CSCs and non-
CSCs in equal amounts, after which the samples were subjected
to gel-assisted trypsin digestion. The phosphopeptides were sub-
sequently purified by immobilized metal affinity chromatography
(IMAC)24 and then subjected to liquid chromatography-tandem
mass spectrometry (LC–MS/MS) in triplicate (Fig. 3a). Quantita-
tive analysis of all identified phosphopeptides was performed
using IDEAL-Q. A total of 835 phosphopeptides from 455 pro-
teins were confidently identified (false-discovery rate < 1%) from
two separate replicates. Detailed information on their identifica-
tion and relative quantitation between the BCSC and non-BCSC
subpopulations are listed in Supporting Information Table S1.
Phosphoproteins with at least twofold upregulation in BCSCs
were analyzed by MetaCore to identify the key signaling pathways
associated with BCSC characteristics. Top ranking pathways with
Figure 1. Greater expression of GPER in BCSCs than in non-BCSCs. (a) Clinical characteristics of the three patients with breast cancer
BC0145, BC0244 and BC0634, from whom the xenografts were derived. (b) Total cell lysates from BCSCs and non-BCSCs sorted from
xenografts of BC0145, BC0244 and BC0634 were subjected to western blotting. GPERs were detected at the bands with a molecular weight in
the 50–55 kDa region. GAPDH protein served as the internal control for normalization. For normalization, total GPER expressions in BCSCs of
BC0145, BC0244 and BC0634 were each set as 1.0 for comparison to values in non-BCSCs. N-BCSC: non-BCSC. (c) Tumor cells from BC0145
and BC0244 xenografts were analyzed for the expression of surface antigens CD24, CD44 and total GPER by flow cytometry. After cells
staining for CD24/CD44, cells were fixed and permeabilized for GPER staining.
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most dramatic upregulation in BCSCs compared to non-BCSCs
were those involved in cytoskeleton remodeling, translation initi-
ation, cell survival and cell cycle progression, based on the
corresponding GeneGo pathway maps (Fig. 3b) and GeneGo
process networks (Fig. 3c). These processes may contribute to
the known metastasis and differentiation characteristics in
BCSCs.15 All differentially expressed phosphoproteins were
further annotated with molecular-function categories in GeneGo
(Fig. 3d). The analysis revealed that elevated phosphoproteins
were enriched in categories involved in the replication of cells
(nucleotide-binding, RNA binding and transcription activity)
and signal transduction (ATP binding, kinase activity, phospha-
tase activity, protein binding and receptor). However, the
molecular functions of ~21% of these differentially regulated
Figure 2. GPER regulation of the survival and stemness of BCSCs. (a) Left panel: AS-B145 or AS-B634 cells were infected with lentiviral
shRNAs and the total proteins were harvested 6 days after infection for western blotting. GAPDH protein served as the internal control for
normalization. The normalized total GPER expression of shLuc cells was set as 1.0 for comparison to values of shGPER infected cells (sh-A,
sh-B and sh-C). Center and Right panels: the growth curve of shRNA infected AS-B145 (shLuc and sh-B) and AS-B634 (shLuc and sh-B) cells
was determined using the xCELLigence system over a period of 72 hr. (b) H2Kd−/CD24−/CD44+ BC0145 cells (left panel) and H2Kd−BC0634
cells (right panel) were infected with shLuc, sh-B or sh-C. GPER mRNA and protein levels were determined by real-time qPCR and western
blotting at 6 days after infection, respectively. The expression of GPER was presented as fold expression relative to shLuc. (c) The cell
proliferation of shRNAs infected H2Kd−/CD24−/CD44+ BC0145 or H2Kd− BC0634 cells were monitored by xCelligence system over a period of
120 hr. (d) Mammosphere formation was assessed for freshly sorted BCSCs from the BC0145 (left) and BC0634 xenograft (right) (2,000
cells/well in a 96-well plate format). Both cell types were infected with shLuc control or shGPER-B. ***p < 0.001 as compared to the control
group using the Student’s t-test.
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phosphoproteins are unknown, making them interesting candi-
dates for future pursuits of their roles in BCSC. Figure 3e showed
the heat map of differentially expressed phosphoproteins in two
independent experiments, grouped into five functional categories
in relation to tumorigenesis (apoptosis, signal transduction, trans-
porter activity) and stem cell characteristics (cell growth and
maintenance, transcription activity). The elevated phosphoryla-
tion levels of almost all of these proteins implicated their roles in
BCSC growth and maintenance, which are supported by publi-
shed studies, including the following examples. (i) For apoptosis,
BAD p-Ser118 was 6.5-fold greater in BCSCs than in non-BCSCs,
which is consistent with observations that BAD p-Ser118 can pre-
vent apoptosis in cancer cells and the expression of BAD can be
used as a marker for chemoresistance of breast cancer.31 (ii) For cell
growth and maintenance, we found that phosphorylation of
Cortactin (CTTN), which is a key player in tumor cell migration,32
was increased up to 4.5-fold in the BCSCs. (iii) For signal transduc-
tion, we found a 14.6-fold increase in phosphorylation of Ser706 in
CD44 from the BCSCs (Supporting Information Table S1). The
presence of phosphorylated CD44 p-Ser706 is required for
hyaluronan-dependent, CD44-mediated growth of melanoma and
prostate cancer.33 (iv) For transcription activity, YAP1, a transcrip-
tion cofactor, was reported to regulate stem cell self-renewal and
differentiation.34 We found that p-Thr63 of YAP1 was higher in
BCSC than non-BCSC (Supporting Information Table S1). Further
validation of greater expression of total YAP1 in BCSC was demon-
strated in the PDXs (BC0145 and BC0244; Supporting Information
Fig. S1). Another protein, STAT1, which requires phosphorylation
at Ser727 for maximal transcriptional activity,35 was found to
have increased phosphorylation at p-Ser727 in BCSC via
Figure 3. Functional analysis of differentially expressed phosphoproteins in BCSCs and non-BCSCs. (a) Workflow diagram for the
phosphoproteomic study, which quantitatively compared the phosphoproteomes of the BCSCs and non-BCSCs sorted from the BC0145
xenograft. Equal amounts of BCSC and non-BCSC lysates, each containing the internal standard β-casein, were enzymatically digested,
enriched in phosphopeptides by IMAC and subjected to triplicate LC–MS/MS. Quantification of the phosphopeptides was performed using
IDEAL-Q software. The phosphoproteins having at least twofold greater expression in BCSCs than in non-BCSCs from two independent
experiments performed in triplicate are shown. (b) The top 10 GeneGo pathway maps (p < 0.001). (c) The top 10 GeneGo process networks (d)
GoMiner analysis showing the distribution of the classified molecular functions of differentially expressed phosphoproteins. (e) Heat maps
for the differentially expressed phosphoproteins identified in duplicated experiments. Quantitative comparison revealed that most of the
differentially expressed phosphoproteins are involved in cell adhesion, cell migration, secretion, cell motility or the cell cycle. (f ) Validation
of selected phosphoproteins. Phosphorylation states of selected phosphoproteins in BCSCs and non-BCSCs from BC0145 and BC0244
xenografts. Western blot analysis of total cell lysates from BC0145 and BC0244 BCSCs and non-BCSCs was performed with antibodies
against BAD, BAD pSer118, PRKACA and PRKACA pThr197. The ratios of expression levels were calculated for the BCSC and non-BCSC
proteins after normalization of their respective signals to the corresponding GAPDH signal. The blots of GAPDH were identical to those in
Figure 1b since the western blot were derived from the same experiment.
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phosphoproteomic analysis (Supporting Information Table S1).
Indeed, western blot analysis of BC0145 confirmed that the level of
STAT1 p-Ser727 in BCSC was 23.8-fold that of non-BCSCs, while
the expression level of total STAT1 was upregulated by only
2.83-fold (Supporting Information Fig. S1).
GPER-related signals were highly expressed in BCSCs
Phosphoproteomic analysis revealed that some GPER-related
proteins or other proteins essential for CSCs properties, such as
PKA and BAD, were more highly phosphorylated in BCSCs than
in non-BCSCs (Supporting Information Table S1). It has been
reported that PKA is an effector of GPCR signaling.36 We specu-
lated that GPER may act as an alternative ER by activating PKA
signaling to promote ER− breast cancer progression. The PKA
holoenzyme contains two cAMP-dependent protein kinase type
I-alpha regulatory subunit (PRKAR1A)-like regulatory subunits
and two cAMP-dependent protein kinase catalytic subunit alpha
(PRKACA)-like catalytic subunits.37 Hence, western blots using
antibodies against PRKACA and phosphorylated PRKACA
(PRKACA pT197) were performed to determine the activation
status of PKA. As shown in Figure 3f, the relative expressions of
PRKACA p-Thr197 and total PRKACA protein in BCSC samples
of BC0145 were 4.73- and 1.71-fold, respectively, of those in non-
BCSCs, after normalization to their corresponding GAPDH.
When normalized to total PRKACA protein, the amount of
PRKACA p-Thr197 in BCSCs was 2.76-fold of non-BCSCs. It
has been reported that BAD, a downstream target of PKA, was
highly expressed in CSCs and phosphorylation of BAD (Ser112
and Ser136) was essential for the survival of CSCs.38 Our phos-
phoproteomes of BC0145 revealed another phosphorylation site
of BAD at Ser118, which was more highly phosphorylated in
BCSCs than in non-BCSCs (Supporting Information Table S1).
Phosphorylation of Ser118 leads to the release of Bcl-XL, thereby
promoting cell survival.39 As shown in Figure 3f, the relative
expressions of p-BAD Ser118 and total BAD protein in BCSC
samples of BC0145 were 7.50- and 4.10-fold, respectively, of those
in non-BCSCs, after normalization to their corresponding
GAPDH. When normalized to total BAD protein, the amount of
p-BAD Ser118 in BCSCs was 1.83-fold of non-BCSCs. A similar
trend was noted in another PDX, BC0244. After normalization to
their corresponding total proteins, the relative abundance of
PRKACA p-Thr197 and p-BAD Ser118 in BCSCs of BC0244
were 1.86- and 1.49-fold, respectively, of non-BCSC subpopula-
tion (Fig. 3f ).
GPER-mediated BAD phosphorylation is essential for the
maintenance of BCSC characteristics
To verify the role of BAD p-Ser118 in BCSCs, we incorporated
the mutant BAD Ser118Ala gene into a doxycycline-inducible
lentiviral vector and infected AS-B145 cells with the vector to cre-
ate a stable clone (Supporting Information Materials and
Methods). Cell proliferation was determined using the
xCELLigence system. Doxycycline-induced expression of the
dominant-negative BAD Ser118Ala mutant significantly
suppressed the proliferation of AS-B145 cells, as compared to
cells expressing wild-type (WT) BAD (p < 0.001; Fig. 4a). Based
on these results, we hypothesized that GPER might trigger PKA-
mediated signaling, causing the release of cAMP and induction of
BAD Ser118 phosphorylation to maintain BCSCs properties.
Since estrogens and the TMX metabolite 4-OHT can induce
GPER-mediated signal transduction that promotes proliferation
and survival in breast cancer cell lines,36 we examined the possible
induction of BAD Ser118 phosphorylation by these agonists of
GPER. Incubation of AS-B145 cells with a pharmacological con-
centration of 4-OHT (2,500 nM) caused a time-dependent
increase in the phosphorylation of BAD Ser118 over the
15–60 min time period (Fig. 4b). Upon 4-OHT treatment, phos-
phorylation of BAD at Ser118 increased to 1.63- to 1.80-fold of
untreated cells. As expected, phosphorylation of another two ser-
ine residues of BAD (Ser112 and Ser136) known to be essential
for the survival of CSCs also increased (Fig. 4b). Since treatment
of AS-B145 cells with 4-OHT upregulated the phosphorylation of
BAD Ser118, we anticipated that GPER ligands such as 4-OHT,
17β-estradiol (E2) and estriol (E3) might influence the survival of
breast cancer cells. Indeed, incubation of AS-B145 and AS-B634
cells with any one of the three ligands for 72 or 48 hr increased
the growth of both types of cell, respectively (Figs. 4c and 4d). In
addition, the effect of GPER activation on promoting cell growth
was further confirmed by treatment of AS-B145 and AS-B634
cells with G1, a specific GPER agonist (Figs. 4c and 4d). We also
determined the expression of GPER by flow cytometry after
exposing AS-B634 cells for 3 days to each of the ligands. All four
agonists significantly increased GPER expression by ~1.4-fold to
~1.9-fold of control cells (1.5-, 1.5-, 1.36- and 1.82-fold for
4-OHT, E2, E3 and G1, respectively; Fig. 4e). We next evaluated
the effects of the GPER ligands on the stemness of AS-B145 cells.
After incubating AS-B145 cells with 4-OHT (2,500 nM), E2
(200 nM), E3 (100 nM) and G1 (100 nM) for 3 days, populations
enriched in BCSCs were identified using the ALDEFLOUR assay
(Fig. 4f ). In these experiments, E3 and G1 treatment led to
increased ALDH+ cell populations (1.59-fold for E3 and 1.88-fold
for G1). Treatment with 4-OHT and E2 led to 1.38-fold and
1.25-fold increases in ALDH+ cell populations, respectively,
suggesting that 4-OHT and E2 may not be as effective as E3 and
G1 in promoting the stemness of BCSCs. Thus, the activation of
GPER indeed promotes stemness.
Depletion of the GPER inhibits BCSCs tumorigenicity
To determine whether the dysregulated GPER contributes to
tumorigenesis in vivo, 1 × 105 of GPER silenced AS-B145 cells
(shGPER) and its control cells (shLuc) were implanted into the
mammary fat pads of 6- to 8-week-old female NSG mice.
Tumor growth was monitored weekly and the mice were
sacrificed 2 months after implantation. As shown in Figure 5,
knockdown of GPER in AS-B145 cells attenuated the growth of
xenograft tumors (Figs. 5a and 5b). To determine the CSC sub-
population, these tumors were digested into single-cell suspen-
sions and stained with CD24 and CD44 markers, followed by
Chan et al. 1681
Int. J. Cancer: 146, 1674–1685 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
Figure 4. GPER signaling includedBADphosphorylation in BCSCs. (a) The growth curve of AS-B145 cells expressing the dominant-negative BAD
Ser118Alamutant. AS-B145 cells were infectedwith a doxycycline-inducible lentiviral vector that expressed themutant BAD orWT BAD. Cell growthwas
measured using the xCELLigence system. Values representmean  SD, n= 3, ***p < 0.001 for BADS118A compared toWTBAD, the cell index at 96 hr
was analyzed by one-way ANOVA. (b) Total cell lysates prepared fromAS-B145 cells that had been treatedwith 4-OHT (2,500 nM) for 15,30,45 or60 min
were immunoblotted. The amount of BADp-Ser118, p-Ser112 and p-Ser136was normalized to the corresponding amount of GAPDH, and the fold increase
in phosphorylationwas normalized to the amount at0min. (c) AS-B145 cells were treatedwith 4-OHT (2,500 nM), E2 (200 nM), E3 (100 nM) or G1
(100 nM) for 72 hr. Cell proliferationwas assessed using the xCELLigence system. The cell index of treated cells at 0hr was set as 1.0, and the cell index of
treated cells at 72 hr relative to the time zero value. Value representsmean  SD, n= 3, *p < 0.05, **p < 0.01 and ***p < 0.001. The statistic was
determined by one-way ANOVA. (d) AS-B634 cells were treatedwith 4-OHT (2000 nM), E2 (50 nM), E3 (100 nM) or G1 (100 nM) for 48 hr. Data
presentation as for Figure 4c. (e) GPER expression of permeabilized AS-B634 cells was assessed byflow cytometry 3days after treatment with 4-OHT
(2000 nM), E2 (50 nM), E3 (100 nM) or G1 (100nM). TheGPER+ population of treated cells was presented as fold increase relative to the control group
(DMSO). The statistic was determined by one-way ANOVA, n= 3, *p < 0.05, **p < 0.01. (f) ALDH activity in AS-B145 cells was assessed by ALDEFLUOR
assay after treatment with 4-OHT (2,500 nM), E2 (200 nM), E3 (100 nM) or G1 (100 nM) for3days. Cell treatedwith diethylaminobenzaldehyde (DEAB),
which is the inhibitor of ALDH,was used to distinguish ALDH+ fromALDH− cells. The ALDH+ populations of treated cells were presented as fold increase
relative to the control group. The statistic was determined by onway ANOVA, n= 3 for 4-OHT, n= 3 for E2, n= 6 for E3 and n= 2 for G1,
*p < 0.05, **p < 0.01.
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flow cytometric analysis. As shown in Figure 5c, CD24−CD44+
cells accounted for 33.7  3.3 and 27.05  3.4% of total cells for
shLuc control tumors and shGPER tumors, respectively. The dif-
ference between the two percentages was not statistically signifi-
cant, presumably due to the resurgence of GPER expression in
shGPER tumors, which was 1.73-fold the control value in the
harvested tumors (Supporting Information Fig. S2). We also
examined the tumorigenicity of shRNAs infected AS-B634 cells
in NSG mice. As shown in Figures 5d and 5e, GPER silencing
significantly retarded the tumor growth. Furthermore, the CSC
subpopulation in the AS-B634 xenograft, as determined by
ALDEFLUOR assay, showed that the average percentage of
ALDH+ cells was significantly higher in shLuc control tumors
than shGPER tumors (25.1  4.3 vs. 8.8  1.2), suggesting that
GPER may sustain the BCSC properties (Fig. 5f ). Taken
together, these data indicate that GPER and its downstream sig-
naling play a key role in the survival and the stemness of BCSCs.
Discussion
Previous studies indicated that GPER agonists stimulate GPER-
dependent cAMP production in several breast cancer cell lines,29
and that the estrogen-induced GPER-dependent PKA pathway is
critical in ameliorating liver injury.40 In our study, we provided
the first evidence that GPER-initiated signaling via PKA activa-
tion and BAD Ser118 phosphorylation are crucial for the survival
of BCSCs. PKA is known as a cAMP-dependent enzyme con-
sisting of regulatory and catalytic subunits. PRKAR1A, one of
four PKA regulatory subunits, is important for the specific activi-
ties of PKA catalytic subunits and for the subcellular localization
of PKA. Increased PRKAR1A expression in human breast carci-
nomas has been shown to correlate with active malignant cell
growth and poor prognosis.41 Reduction of PRKAR1A expres-
sion by antisense inhibition causes growth inhibition and apo-
ptosis, which is attributed to hypophosphorylation of BAD and
hyperphosphorylation of Bcl-2.42 In our phosphoproteomics
Figure 5. The tumorigenicity of GPER in BCSCs. (a) AS-B145 cells were infected with lentiviral shLuc or shGPER for 6 days. Cells (1 × 105) infected
with shRNAs were implanted into the mammary fat pads of 6- to 8-week-old female NSGmice (n = 6). Photos show the tumors of individual mice
after sacrifice. The black line represents 1 cm. (b) The tumor growth curves in individual mice of each group during the 2months after implantation.
(c) Due to the small tumor sizes, six shLuc and four shGPER tumors were digested into single cells suspension and stained with H2Kd/CD24/CD44
antibodies to determine the BCSC subpopulation. The mean percentages of H2Kd−/CD24−/CD44+ cells in the total tumor cell population in the shLuc
and shGPER are shown. Values represent mean  SD, p = 0.2, Student’s t-test. (d and e) AS-B634 cells (5 × 104) infected with shRNAs were
implanted into the mammary fat pads of 6- to 8-week-old NSG mice (n = 5). The tumor growth curves in individual mice during the 4 weeks after
implantation are shown (five shLuc and five shGPER tumors). (f ) Tumors (five shLuc and four shGPER tumors) were digested and stained with using
the ALDEFLUOR assay. The mean percentages of ALDH+ cells in the total tumor cell population in the shLuc and shGPER groups are shown. Values
represent mean  SD, *p < 0.05, Student’s t-test. (g) Schematic illustration of GPER signal transduction pathway involved in the regulation of
survival and stemness of BCSCs. Treatment of GPER+ breast cancer cells with GPER agonists (TMX, E2 and E3) triggers cAMP production, which in
turn induces phosphorylation of PKA and BAD, thereby promoting cell proliferation and sustaining CSCs.
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studies, not only was Thr197 of PRKACA highly phosphorylated
in BCSCs but the phosphorylation at Ser83 of PRKAR1A was
higher in BCSCs than non-BCSCs (Supporting Information
Table S1). However, the exact role of phosphorylation at Ser83
of PRKAR1A in the regulation of the PKA holoenzyme and in
BCSCs remains unclear and awaits future studies. Moreover,
phosphorylation of BAD Ser118 results in increased glucokinase
activation with ensuing ATP production in mitochondria,43
which could account for our observed increases in proliferation
of breast cancer and BCSCs upon exposure to GPER agonists.
Increased phosphorylation of PRKAR1A Ser83 and BAD Ser118
may, therefore, contribute to BCSC survival.
There is increasing evidence for the importance of modu-
lating GPER signaling in the treatment of breast cancer. In
recent years, many chemicals have been identified as agonists
or antagonists of GPER.44 Although 4-OHT, E2, E3 and G1
have been reported to be GPER ligands, their downstream sig-
nals exhibited both overlapping and unique profiles, even
within the same breast cancer cell line.45 In our studies, this is
further complicated since two different PDXs and their
derived cell lines which may contribute to variations in their
responses to each chemical. Among the four GPER agonists
investigated, G1 appeared to induce greater increases in the
number of GPER+ cells and ALDH+ cells than the others. This
might reflect greater specificity of G1 for GPER than the
others. Furthermore, pathologic features such as ER, PR and
HER2 status may also affect GPER signaling. Although GPER
expression had no correlation with the status of ER, PR and
HER2 expression in primary breast cancers,46 the crosstalk
between GPER and ErbB receptors has been reported. For
instance, EGFR transactivation upon activation of GPER has
been documented in breast cancer.7 In addition, since certain
ER antagonist, such as TMX may serve as GPER agonist,11
the expression status of ER may affect the response of GPER
expressing cells to TMX. In view of the complex interactions
between GPER and ER/PR/HER2 pathways, ER-negative
PDXs used in our study may lessen the impact of ER on
GPER signaling. Our findings not only demonstrated a key
role of GPER in the survival and tumor-initiation capacity of
BCSCs but also provide a molecular mechanism underlying
increased tumorigenicity mediated by GPER.
Current evidence suggests that subpopulations of cancer
cells with stem cell-like properties may drive tumor growth
and metastasis.15 By virtue of their relative resistance to
current therapeutic approaches, these cells may contribute to
treatment failure and relapse. Thus, to improve therapeutic
efficacy, other strategies must be developed to effectively tar-
get populations of cancer stem cells. However, the signal
transduction pathways important to stem cell properties have
not been systematically elucidated. In our phosphoproteomics
analyses, we identified 455 phosphoproteins that were differ-
entially regulated in many of the signal transduction pathways
associated with the stemness characteristics of self-renewal
and cell survival, as well as with tumorigenesis. These signal
pathways and their networking revealed many phosphopro-
teins with unknown functions as well as novel phosphoryla-
tion sites of known proteins, which may be targeted for future
investigations.
GPER plays a multifaceted role in metabolic disorder47 and
cancer. In cancer progression, GPER can encourage the
growth of breast cancer cells via the upregulation of c-Fos.48
Besides, GPER enhances cellular adhesivity and fibronectin
matrix assembly and allows for anchorage-independent
growth via Shc-dependent pathway.49 In addition, GPER can
promote the process of epithelial–mesenchymal transition
(EMT) via upregulating Snail expression through the crosstalk
between GPER and the Notch signaling pathway, as demon-
strated by incubating breast cancer cell line with estradiol.50
Another study has demonstrated that GPER agonists-induced
signaling in cancer-associated fibroblasts upregulates the
expression of connective tissue growth factor (CTGF), which
in turn promotes migration of breast cancer cells.8 Apart from
these possible mechanisms by which GPER may contributes
to carcinogenesis, we found that GPER agonists increased cell
proliferation and the BCSC population via p-PKA/p-BAD sig-
naling (Fig. 5g). In conclusion, our studies revealed a vital role
of GPER-mediated signaling pathways in BCSC survival,
suggesting that the identification of GPER-specific antagonists
may provide new therapies for breast cancer.
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